Drug intelligence / Profile preview

SCRI-CAR19v3

Development stage: Phase 1
Lead developer: Seattle Children's Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

SCRI-CAR19v3 is an autologous chimeric antigen receptor T cell (CAR-T) therapy developed by Seattle Children's Hospital. It is designed to treat immune-mediated diseases, specifically targeting B-lymphocyte antigen CD19 (CD19) on B cells. The therapy involves collecting a patient's own T cells, genetically modifying them to express a CD19-specific CAR, and then infusing them back into the patient. The engineered CAR-T cells recognize and eliminate CD19-expressing B cells through immunologic cytotoxicity. SCRI-CAR19v3 is currently being investigated in a phase 1 clinical trial for pediatric and young adult patients with treatment-refractory systemic lupus erythematosus (SLE)[1][2][4].

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on SCRI-CAR19v3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCRI-CAR19v3.

Explore the full profile